AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 81 min read$ENGN

EnGene Therapeutics Inc. Earnings At $32.50 Mln In Q3

EnGene Therapeutics Inc. (ENGN) reported Q3 earnings of $32.50 million, or $0.47 per share, down from $28.99 million, or $0.57 per share, in the same period last year.

Original reporting
rttnews.com
Published Sep 8, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ENGN
Neutral
medium confidence
Mentioned
$ENGN
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ENGNNeutralLow
01

Why it matters

The Q3 profit increase provides a small positive data point but does not change the overall growth outlook.

02

Market read

Earnings release offers limited trading opportunity due to small scale.

03

What to watch

Potential pipeline developments not disclosed could be material.

Relevance 5/10Novelty 5/10Timing: Q3 earnings release

Background

EnGene Therapeutics is a biotech company focused on gene‑editing therapies.

Company-level read

Ticker impact

$ENGNNeutralMedium confidence
Context

EnGene Therapeutics reported Q3 profit of $32.5 million and EPS of $0.47, up from $28.99 million and $0.57 last year.

Expected impact

Modest upside potential if investors focus on earnings beat.

Evidence & confidence

The earnings numbers are new but the scale is modest; price reaction likely muted.

Market effects

Sector

Limited effect on biotech sector; earnings beat is modest.

Regional

No significant regional impact.

Global

Low global relevance.

Counterpoint

What could challenge this read

Investors may view the earnings beat as insufficient given the decline in EPS.

Key entities

  • Company
    EnGene Therapeutics Inc.

    Biotech firm reporting Q3 earnings.

Read at source← All news

Related articles

SEP 8
$ENGNMed

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics reported Q3 2026 financial results, with $266.3M in cash and a net loss of $32.5M. The company plans to update key regulatory data, hold a pre-BLA meeting, and initiate a BLA submission for detalimogene in Q4 2026. It also announced a surfactant safety run-in clearance and a webinar on preclinical data. The company is well-capitalized to support BLA filing and precommercial readiness.

leaderpost.com3 min
SEP 8
$ENGNMedAI 9/10

enGene Therapeutics Inc. 3Q FY2026: Net loss $32.5M, EPS ($0.47) — 10-Q Summary

enGene Therapeutics Inc. reported a net loss of $32.5M for 3Q FY2026, an increase from $29M in the same period last year. Diluted loss per share was $0.47, an improvement from $0.57. The company had no product revenue. Clinical progress was noted in the LEGEND study, with a 54% any-time complete response rate. The company plans to submit a BLA in Q4 2026 and expects cash to last at least 12 months.

tradingview.com1 min
SEP 8
$ENGNMed

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enGene Reports Third Quarter 2026 Financial Results and Provides Business Update Data update on key regulatory endpoints, complete response (CR) at any time and maturing durability, as well as landmark CR rates from LEGEND's pivotal cohort planned for 4Q 2026 Pre-Bio

SEC EDGAR 8-K2 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 15
$ENGNMed

enGene Therapeutics Inc. (ENGN): Results of Operations and Financial Condition

enGene Therapeutics Inc. (ENGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 engn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 enGene Reports Second Quarter 2026 Financial Results and Provides Business Update 12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Ap

SEC EDGAR 8-K6 min